BioMarin Just Torched $270 Million on a Drug That Couldn't Deliver

This is one of the most frustrating outcomes in drug development. It's like acing the written portion of a driving test while failing every single turn behind the wheel. The mechanism looked right; the clinical reality didn't follow.

$270 Million Up in Smoke

The company removed BMN 401 from its pipeline entirely, and the $270 million it spent acquiring Inozyme is now, for all practical purposes, a write-off.

Wall Street's reaction was swift but not catastrophic. Shares fell roughly 4% as investors digested the news. Stifel called the readout a sign of "significant risk" and noted that the failure removes an upside driver from BioMarin's growth story.

But other analysts took a more measured view. The bull case for BioMarin was never really about BMN 401. It was always about VOXZOGO, the company's blockbuster treatment for achondroplasia (a form of dwarfism), and the broader enzyme-therapy portfolio it bolstered by acquiring Amicus Therapeutics.

BioMarin's Bigger Picture Hasn't Crumbled

If you zoom out, BioMarin still has a lot going for it. VOXZOGO remains the crown jewel, with the company pursuing a new filing for hypochondroplasia and eyeing a potential 2027 launch. BMN 333, a long-acting therapy for achondroplasia, is advancing toward registration-enabling studies. And the Amicus deal added two marketed products (GALAFOLD and POMBILITI + OPFOLDA) that helped BioMarin raise its 2026 revenue outlook.

The company also quietly stepped away from ROCTAVIAN, its gene therapy for hemophilia A, saying it would no longer market the product in 2026. That's a separate story, but it paints a picture of a company actively pruning its portfolio to focus on what's working.

The BMN 401 failure doesn't break BioMarin. But it does sting, both financially and strategically.

Rare Disease Is a High-Wire Act Without a Net

BioMarin's stumble fits a painful pattern that's played out across rare-disease biotech in 2025 and 2026. The graveyard of expensive Phase 3 failures keeps growing.

Ultragenyx lost about $1 billion in market value after setrusumab failed in osteogenesis imperfecta, a brittle-bone disease. AstraZeneca watched its efzimfotase alfa program miss the mark in hypophosphatasia. Applied Therapeutics saw govorestat fail in a Phase 2/3 trial for SORD deficiency, compounding a prior FDA rejection.

The common thread: in rare disease, everything rides on a single pivotal trial. The patient populations are small, the biology is complex, and there's no room for a "close enough" result. You either clear the bar or you don't. BioMarin didn't.

What This Means Going Forward

BioMarin's portfolio reassessment isn't about retreating from rare disease. It's about doubling down on programs with clearer paths to approval and commercial returns. VOXZOGO and BMN 333 sit at the top of that priority list. The Amicus-acquired products provide near-term revenue stability. Earlier-stage bets like BMN 351 (for Duchenne muscular dystrophy) offer longer-dated optionality.

For investors, the takeaway is nuanced. Losing BMN 401 removes a potential future revenue stream, but it wasn't the reason most people owned the stock. Analyst price targets remain wide, reflecting genuine disagreement about how much this setback should matter to the long-term thesis.

For the broader biotech world, the lesson is one the industry keeps learning the hard way: a biomarker win without a clinical win is just an expensive science experiment. Moving molecules in the bloodstream is great. Moving the needle for patients is what actually counts.

BioMarin will survive this. But somewhere in San Rafael, California, someone is staring at a $270 million line item and wondering what could have been.

Merck's Drug Aced One Test and Bombed the Other. That Tells Us a Lot.

Merck's tulisokibart just delivered a perfect split: a Phase 2 win in hidradenitis suppurativa and a flop in lung disease. The results reveal exactly why anti-inflammatory drugs keep hitting a wall in fibrotic conditions, and what it means for Merck's $10.8 billion bet.